Systemic sclerosis (scleroderma) and cancer risk: Systematic review and meta-analysis of observational studies

Rheumatology (United Kingdom)

Volumn 52, Issue 1, 2013, Pages 143-154

  Bonifazi, Martina ^a,b   Tramacere, Irene ^a   Pomponio, Giovanni ^d   Gabrielli, Barbara ^b,d   Avvedimento, Enrico V ^e   La Vecchia, Carlo ^a,c   Negri, Eva ^a   Gabrielli, Armando ^b,d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer; Meta analysis; Risk; Scleroderma; Systematic review; Systemic sclerosis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; DISEASE ASSOCIATION; EMBASE; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MEDLINE; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; POPULATION; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS;

COMORBIDITY; HUMANS; INCIDENCE; NEOPLASMS; RISK; SCLERODERMA, SYSTEMIC;

EID: 84871131309     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes303     Document Type: Article

References (47)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008;37: 223-35.
3. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2-10.
4. Hochberg M, Silman A, Smolen J, Weinblatt M. Epidemiology and classification of scleroderma. St Louis: Mosby 2010.
5. Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol 1979;115:950-5.
6. Zatuchni J, Campbell WN, Zarafonetis CJ. Pulmonary fibrosis and terminal bronchiolar (alveolar-cell) carcinoma in scleroderma. Cancer 1953;6:1147-58.
7. Talbott JH, Barrocas M. Carcinoma of the lung in progressive systemic sclerosis: a tabular review of the literature and a detailed report of the roentgenographic changes in two cases. Semin Arthritis Rheum 1980;9: 191-217.
8. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of randomised controlled studies in meta-analysis. www.Ohri.Ca/programs/clinical-epidemiology/oxford.htm (19 October 2007, date last accessed).
9. Greenland S. Variance estimators for attributable fraction estimates consistent in both large strata and sparse data. Stat Med 1987;6:701-8.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
11. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56: 455-63.
12. Villa AR, Kraus A, Jimenez-Corona A et al. Malignant neoplasms in autoimmune rheumatic diseases: examination of the risk of developing a malignancy among five different rheumatic diseases in one institution. J Clin Rheumatol 2000;6:176-83.
13. Siau K, Laversuch CJ, Creamer P, O'Rourke KP. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int 2011;31:641-5.
14. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910-4.
15. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415-24.
16. Derk CT, Rasheed M, Spiegel JR, Jimenez SA. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol 2005;32:637-41.
17. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993;36:460-4.
18. Kang KY, Yim HW, Kim IJ et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol 2009;38: 299-303.
19. Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 2011;117: 1163-71.
20. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33:1113-6.
21. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010;163: 800-6.
22. Kuo CF, Luo SF, Yu KH et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2012;41:44-9.
23. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728-31.
24. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985;12:1136-9.
25. Roumm AD, Medsger TA Jr. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 1985; 28:1336-40.
26. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 2001;21: 106-11.
27. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006;18:129-34.
28. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10:R45.
29. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy risk in autoimmune rheumatic diseases. Discov Med 2005; 5:534-7.
30. Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 2011;104:1478-81.
31. Bernatsky S, Ramsey-Goldman R, Gordon C, Clarke AE. Prostate cancer in systemic lupus erythematosus. Int J Cancer 2011;129:2966-9.
32. Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative damage in systemic sclerosis. J Rheumatol 2010;37:2540-7.
33. Svegliati S, Cancello R, Sambo P et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005;280: 36474-82.
34. Martins EP, Fuzzi HT, Kayser C et al. Increased chromosome damage in systemic sclerosis skin fibroblasts. Scand J Rheumatol 2010;39:398-401.
35. Rittner G, Schwanitz G, Baur MP et al. Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes. Hum Genet 1988;81:64-70.
36. Wolff DJ, Needleman BW, Wasserman SS, Schwartz S. Spontaneous and clastogen induced chromosomal breakage in scleroderma. J Rheumatol 1991;18:837-40.
37. Failli P, Palmieri L, D'Alfonso C et al. Effect of n-acetyl-l-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis. Nitric Oxide 2002;7:277-82.
38. Bocchino M, Agnese S, Fagone E et al. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. PLoS One 2010;5:e14003.
39. Wallach-Dayan SB, Izbicki G, Cohen PY, Gerstl-Golan R, Fine A, Breuer R. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/Fasl pathway. Am J Physiol Lung Cell Mol Physiol 2006;290:L790-6.
40. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995;38:1120-7.
41. Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. J Rheumatol 2008; 35:11-3.
42. Landgren O, Engels EA, Pfeiffer RM et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006;98:1321-30.
43. Gadalla SM, Amr S, Langenberg P et al. Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer 2009;100:817-21.
44. Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010;95:1216-20.
45. Black KA, Zilko PJ, Dawkins RL, Armstrong BK, Mastaglia GL. Cancer in connective tissue disease. Arthritis Rheum 1982;25:1130-3.
46. Higuchi M, Horiuchi T, Ishibashi N, Yoshizawa S, Niho Y, Nagasawa K. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000;19:123-6.
47. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008;111: 3388-94.